ImmuPharma plc is a drug discovery and development company. The Company focuses on developing drugs, based on peptide therapeutics, to treat medical conditions such as autoimmune diseases. The Company has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). As of December 31, 2011, the Company had five drug candidates, such as Lupuzor to treat lupus; IPP-204106, to treat cancer; IPP-201007 to treat inflammation/allergic conditions, such as asthma and rheumatoid arthritis; IPP-102199 to treat moderate to severe pain, such as cancer and postoperative pain, and IPP-203101to treat severe resistant hospital-acquired infections, such as methicillin-resistant staphylococcus aureus (MRSA). As of March 27, 2012, Lupuzor received approval from the Food and Drug Administration to start a Phase III trial.